CFO of Privia Health Uses Rule 10b5‑1 Plan to Buy Shares at $2 and Sell at $25—Insider Confidence Signals a Potential Rally

Insider Activity Spotlight: Privia Health Group Inc.

Short‑Term Buying Surge Amid a Stable Price On May 1, 2026, EVP and CFO David Mountcastle executed a Rule 10b5‑1 buy of 7,179 shares at roughly $2 each, immediately followed by a sale of the same amount at the market price of $25.03. The buy was part of a pre‑planned trading schedule and coincided with the company’s share price hovering near its 52‑week high of $26.51. The timing—just before a modest weekly decline of 2.21%—suggests a strategy to lock in a low entry point before a likely rebound, a pattern that investors often view favorably when insider confidence is high.

Volume of Options Exercised Signals Confidence Mountcastle also liquidated a substantial block of vested options (over 9,000 shares) on the same day. These sales, all executed at $0, reflect a routine exercise of rights rather than an attempt to profit from stock price movements. Combined with his consistent pattern of buying and selling under Rule 10b5‑1 plans, the moves indicate disciplined, rule‑compliant trading rather than opportunistic dumping. For shareholders, this can be reassuring: the CFO is following a structured plan and does not appear to be reacting to insider information.

Historical Patterns Reinforce a Long‑Term View Over the past year, Mountcastle has sold and purchased shares in a balanced manner—selling large blocks in March and early April when the price ranged $20–25, and buying back in February when the price dipped to $2.00. The 10b5‑1 framework has been employed consistently, underscoring a long‑term confidence in Privia’s valuation. His option exercises, all fully vested, align with the company’s grant policies and reflect routine equity compensation management.

Implications for Investors

1. Signal of Management Confidence: Regular buying under a 10b5‑1 plan, especially at low prices, often signals that insiders believe the stock is undervalued. The CFO’s recent purchase at $2 suggests he sees upside potential.
2. Reduced Insider Sell Pressure: The bulk of option sales are executed at $0, not at market value, indicating that insider selling is largely driven by compensation rather than a need to liquidate.
3. Potential for Upside: With a market cap of $3.1 billion and a 12.51% monthly gain, Privia is positioned well within the healthcare platform niche. The CFO’s actions could foreshadow a rally as the company expands its physician‑enablement ecosystem.

Looking Ahead Investors should watch for the next scheduled trades in Mountcastle’s 10b5‑1 plan, as well as any corporate announcements that could materially affect the platform’s growth trajectory. If the CFO continues to buy on dips and hold through volatility, it could serve as a bullish cue for both short‑ and long‑term investors.